Albany Molecular Research, Inc. announced a restructuring of several research departments and corresponding senior management promotions.
Michael P. Trova, Ph.D. has been named to the newly created position of senior vice president, chemistry. In his new role, Dr. Trova assumes responsibility and oversight for AMRI's broad chemistry services business, encompassing medicinal chemistry, chemical development, combinatorial chemistry/parallel synthesis and analytical services. Most recently, Dr. Trova served AMRI as senior vice president, medicinal chemistry. Dr. Trova has been with AMRI since 1995, when he joined the company as an assistant director of medicinal chemistry. He has received several promotions since then, culminating in today's announcement. Dr. Trova received his Ph.D. in organic chemistry from Ohio State University and performed postdoctoral studies at the Massachusetts Institute of Technology. Prior to joining AMRI, Dr. Trova was a research scientist at Lederle Laboratories, a division of American Cyanamid Company, now part of Wyeth.
Bruce J. Sargent, Ph.D. has been promoted to the newly created position of vice president, discovery research and development. In addition to working with Dr. Trova in leading medicinal chemistry research efforts, Dr. Sargent also assumes responsibility for AMRI's proprietary technology platforms and discovery R&D investments. Included in these areas are AMRI's operations in natural products technologies, drug discovery screening, discovery collaborations, internal research investments, and biosciences. Dr. Sargent joined AMRI's medicinal chemistry leadership team in 2001 from Knoll Ltd, the UK-based division of BASF-Pharma, where he was head of chemistry and managed research initiatives in several therapeutic areas. He obtained his Ph.D. in chemistry from the University of Manchester in the United Kingdom.
Patricia Ellis has been promoted to vice president, quality and regulatory affairs. In her new role, Ms. Ellis will oversee quality control and regulatory compliance at all of AMRI's GMP manufacturing facilities, as well as manage the company's relationship with regulatory agencies, including the U.S. Food and Drug Administration. Ms. Ellis has 35 years of pharmaceutical industry experience, beginning with Sterling Drug as an analytical chemist. She served as vice president of quality affairs at Organichem Corporation, which was merged into AMRI in 2003. Ms. Ellis is a graduate of Russell Sage College, and received a master's degree in management from Rensselaer Polytechnic Institute.
Kenton Shultis, vice president and general manager at AMRI's wholly owned manufacturing subsidiary, Organichem Corporation, has assumed the added responsibility for all of AMRI's cGMP synthesis and manufacturing efforts, encompassing operations both at Organichem and at AMRI's 21 Corporate Circle facility. Mr. Shultis has twenty-five years of pharmaceutical industry experience that includes positions at Abbott Laboratories, Merck and Bristol-Myers Squibb. Before joining AMRI in 2000, Mr. Shultis was co-founder of American Advanced Organics, Inc., a company later purchased by AMRI. He received his master's degree in chemical engineering from the University of Minnesota.
Barbara Galbiati, Ph.D. has been promoted to director of analytical quality services. In her new role, she will be responsible for overseeing the company's analytical quality services department, which provides analytical support to cGMP manufacturing projects, including analytical method development, quality control, and related functions. Dr. Galbiati joined AMRI in 2002. Her previous experience includes positions at Italfarmaco Research Center in Milan, as well as Honeywell Pharmaceutical Fine Chemicals. She received her Ph.D. in pharmaceutical chemistry and technology from the University of Milan, Italy.
AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D. said, "These promotions crown a restructuring of AMRI's scientific and technical operations, and acknowledge the continuing growth, evolution and implementation of our strategic plan covering our chemistry services platform, our cGMP synthesis and manufacturing business, and the investments in value-added technologies and internal research initiatives. It is my pleasure to congratulate and acknowledge each of these managers as they assume increasing responsibility within our organization and take these important steps in their careers. As AMRI continues to evolve, I am confident that the contributions of each of these leaders will have a significant impact in achieving the high expectations we have set for our business."